Pharmaceutical Technology

JULY 26, 2022

NewAmsterdam Pharma has signed a definitive business combination agreement with special purpose acquisition company (SPAC) Frazier Lifesciences Acquisition (FLAC). The deal will make NewAmsterdam Pharma a publicly listed company focusing on oral treatments for cardiometabolic diseases.

Pharma 59

Pharma Specialization Healthcare Healthcare 59

pharmaphorum

OCTOBER 14, 2022

A consortium of industry and academic groups – led by Johnson & Johnson’s pharma division Janssen – has been set up to tackle the environmental impact of digital health products, specifically aimed at minimising waste that could end up in landfill. The project started on 1 October and is scheduled to complete in September 2026.

Leads 124

Leads Electronics Ethics Healthcare 124

PM360

SEPTEMBER 21, 2023

Under the pathway, manufacturers can use safety and efficacy data from existing products in their applications for their own products. The product, manufactured by ARS Pharma and Neurelis Pharma, would be the first needle-free epinephrine alternative to autoinjectors, such as the EpiPen.

Management 105

Management Manufacturing Sales Competition 105

pharmaphorum

JANUARY 18, 2023

NewAmsterdam Pharma’s bold play to resurrect an all-but defunct cholesterol-lowering drug class has been rewarded with a positive phase 2 trial of its oral CETP inhibitor obicetrapib. Amgen licensed the rights to NewAmsterdam in 2020.

Pharma 59

Pharma Prospecting Patients Safety 59

pharmaphorum

JULY 26, 2022

NewAmsterdam Pharma has charted out a route to a Nasdaq listing by merging with black cheque company Frazier Lifesciences in a deal that will provide additional cash for its main drug candidate – oral CETP inhibitor obicetrapib. Remember CETP? Amgen licensed the rights to NewAmsterdam in 2020.

Side effects 52

Side effects Safety Pharma Patients 52

pharmaphorum

DECEMBER 21, 2022

Since September, it has been led by president and CEO Sujay Kango – also on the boards of MEI Pharma and Infinity Pharma – who has no doubt focused his attentions on getting the Kite deal over the line since taking on the role. Image by Anja from Pixabay .

Pharma 52

Pharma Manufacturing Engineering Safety 52

Pharma Marketing Network

MAY 12, 2021

Billion by 2026 with a CAGR of 37.2% Physicians and patients raise legitimate questions and concerns about the safety, effectiveness, and accessibility of telehealth. The post A Look Into Telehealth in 2021 and Beyond appeared first on Pharma Marketing Network. Billion in 2019 and Expected to Reach USD 171.81

Physicians 59

Physicians Patients Safety Marketing 59